文摘
摘要目的:评估不同的灰质和白质线区域方法之间的关系进行量化的损失函数在多发性硬化(MS)患者,一群患者和健康对照组接受核磁共振成像(MRI)和神经功能评估从三个视角:医师评估使用传统方法(P)、问卷调查对patient-interpreted残疾(Q);使用感觉运动器械(I)考试。
背景:传统上,感觉运动功能还没有被很好地与大脑MRI病灶和萎缩相关测量。然而,脊髓萎缩已被证明与残疾女士。
设计/方法:50 MS患者(23人,27名女性)+ 10健康对照组,18 - 70岁接受MRI扫描,包括一个轴向PSIR C2-C3颈椎的扫描。线图像分割使用吉姆7.0计算共线区(TCA)和灰质区(GMA)。医生评价指标包括eds(规模扩大残疾状态),25英尺步行时间和测试(9成9洞挂钩。问卷包括病人报道eds(仅仅),动态指数(AI),残疾,神经评定量表、功能规模,走援助,WHODAS。工具性考试采用microFET-neck /手臂力量测功器,电磁共振器多频灵敏度测试仪(VMST)和Jamar测功机的控制。线区域和每个功能指标之间的相关性和疾病持续时间和调整性计算。套索回归模型分别对每个类的功能指标选择模型,预测线地区,包括所有的变量。
结果:疾病持续时间和各类功能相似度指标预测柠檬酸和GMA: TCA-R2= 29% (P), 29% (Q), 34%(我);GMA-R2= 36% (P); 42% (Q), 42%(我)。只有9 hpt (P),仅仅(Q)和FET-neck VMST (I)被选为这些模型。功能指标的相关性与线区域调整为性(TCA-p = 0.097;GMA-p = ns)和疾病持续时间(TCA-p = 0.004;GMA-p = 0.0087),辅助变量(VMST TCA-p = ns, GMA-p = 0.0043;FET-neck TCA-p = < 0.0001, GMA-p = 0.0014;控制TCA-p = 0.0004, GMA p = 0.018),仅仅(TCA-p = 0.0002, GMA-p = 0.001)和9 hpt (GMA-p TCA-p = 0.008, = 0.0081)显示的相关性。
结论:相比之下,工具性考试(FET-neck VMST)最好的预测总和脊髓灰质的发现。然而,病人问卷(仅仅,AI)也与核磁共振的发现。
披露:亚历山大博士没有披露。Arjona博士没有披露。Papinutto博士没有披露。斯特恩博士没有披露。女孩收到个人赔偿咨询博士担任科学顾问委员会,说,或其他活动Idec, Actelion股价。博士没有披露。盖尔芬德博士已经收到个人赔偿咨询、担任科学顾问委员会说,与生原体或其他活动,落实Quest Diagnostics,政府和商业实体医疗法律咨询。盖尔芬德博士已经收到个人薪酬在一篇社论中力学的能力。盖尔芬德博士已经收到研究基因泰克和MedDay的支持。Goodin博士已经收到个人赔偿咨询、担任科学顾问委员会说,与生原体或其他活动,拜耳先灵葆雅,诺华,EMD Serono, Genzyme和梯瓦制药。 Dr. Jia has nothing to disclose. Dr. Romeo has nothing to disclose. Dr. Graves has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genentech, Inc. and S3 Group. Dr. Graves has received research support from Biogen and Genentech. Dr. Cree has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Abbvie, Akili, Biogen, EMD Serono, GeNeuro and Novartis. Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon, Symbiotix, Bionure and Neurona; he has also received travel reimbursement from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentation. Dr. Henry has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consultancy from Novartis, Medday, Roche, Sanofi-Genzyme, Abbvie. Educational programs from Sanofi-Genzyme, TEVA. Dr. Henry has received research support from Research support from Sanofi-Genzyme, Roche/Genentech, Medday.
